Grufity logoGrufity logo

ResMed Inc Stock Research

RMD

211.28USD+3.29(+1.58%)Market Closed

Market Summary

USD211.28+3.29
Market Closed
1.58%

RMD Alerts

RMD Stock Price

RMD RSI Chart

RMD Valuation

Market Cap

31.0B

Price/Earnings (Trailing)

38.34

Price/Sales (Trailing)

8.25

EV/EBITDA

29.54

Price/Free Cashflow

131.11

RMD Price/Sales (Trailing)

RMD Profitability

EBT Margin

26.57%

Return on Equity

21.65%

Return on Assets

12.12%

Free Cashflow Yield

0.76%

RMD Fundamentals

RMD Revenue

Revenue (TTM)

3.8B

Revenue Y/Y

15.52%

Revenue Q/Q

8.78%

RMD Earnings

Earnings (TTM)

809.5M

Earnings Y/Y

11.48%

Earnings Q/Q

6.86%

Price Action

52 Week Range

188.66260.79
(Low)(High)

Last 7 days

-3.1%

Last 30 days

-3.3%

Last 90 days

-3.3%

Trailing 12 Months

-14.3%

RMD Financial Health

Current Ratio

3.17

Debt/Equity

0.48

Debt/Cashflow

0.21

RMD Investor Care

Dividend Yield

0.81%

Dividend/Share (TTM)

1.72

Shares Dilution (1Y)

0.62%

Diluted EPS (TTM)

5.51

Peers (Alternatives to ResMed)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
104.1B
18.4B
2.26% 8.00%
44.16
5.64
7.84% 18.25%
84.2B
6.2B
-4.47% -13.27%
63.66
13.53
8.97% -22.43%
69.1B
12.7B
0.59% 12.45%
99.06
5.45
6.68% -32.95%
67.4B
19.0B
-5.16% -6.78%
41.86
3.55
-0.43% -8.78%
49.8B
5.4B
2.41% -25.12%
32.74
9.26
2.86% 1.25%
MID-CAP
7.2T
489.7M
9.34% 31.15%
82.2K
16.8K
106.51% 2464.23%
10.2B
847.1M
-3.64% 34.52%
-5.1K
12.05
13.32% -137.89%
5.2B
1.0B
-11.64% -20.31%
30.19
5.09
6.76% 24.45%
3.5B
410.9M
4.51% -3.13%
-29.82
8.43
27.29% -14.60%
2.7B
801.2M
1.13% -58.87%
-28.25
3.34
14.00% -707.69%
SMALL-CAP
1.7B
138.6M
-15.68% 29.18%
-30.43
12.07
36.62% -10.44%
1.6B
350.9M
10.38% 49.06%
-10.84
4.7
44.26% -5.42%
1.3B
820.0M
-8.35% -12.22%
25.89
1.59
10.13% 701.59%
828.4M
239.8M
0.30% 1.49%
-21.88
3.45
-4.74% -31.15%

Financials for ResMed

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue3.8%3,7633,6243,5783,5393,444
Gross Profit3.7%2,1342,0592,0241,9931,949
Operating Expenses4.2%1,0891,0451,0241,006973
  S&GA Expenses3.5%783757739726704
  R&D Expenses2.9%264257254249238
EBITDA2.7%1,1031,0741,0981,095-
EBITDA Margin-1.1%0.29*0.30*0.31*0.31*-
Earnings Before Taxes3.8%1,000963960962953
EBT Margin-0.1%0.27*0.27*0.27*0.27*-
Interest Expenses-9.4%-51.09-46.70-22.31-47.81-47.45
Net Income2.9%809786779779522
Net Income Margin-0.9%0.22*0.22*0.22*0.22*-
Free Cahsflow-27.1%237325216364-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets28.9%6,6765,1785,0964,9054,735
  Current Assets14.3%2,3252,0341,9311,7041,547
    Cash Equivalents22.2%253207274202194
  Inventory14.3%989865744665592
  Net PPE7.3%523487498513478
  Goodwill42.7%2,7671,9391,9361,9461,951
Liabilities68.4%2,9381,7451,7351,6261,589
  Current Liabilities5.8%733693689667621
.    Short Term Borrowings-0.1%10.0010.0010.0012.0012.00
  Long Term Debt128.0%1,791785765669668
Shareholder's Equity8.9%3,7383,4333,3613,2793,146
  Retained Earnings4.3%3,9203,7603,6143,4803,363
  Additional Paid-In Capital0.5%1,7111,7021,6821,6451,629
Shares Outstanding0.3%147146146146146
Float-37,771----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-19.8%370461351498577
  Share Based Compensation0.6%65.0065.0065.0066.0066.00
Cashflow From Investing-382.1%-1,189-246-229-222-231
Cashflow From Financing437.2%888-263-128-299-397
  Dividend Payments1.3%252249245241236

Risks for RMD

What is the probability of a big loss on RMD?

62.3%


Probability that ResMed stock will be more than 20% underwater in next one year

26.9%


Probability that ResMed stock will be more than 30% underwater in next one year.

0%


Probability that ResMed stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RMD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ResMed was unfortunately bought at previous high price.

Drawdowns

Returns for RMD

Cumulative Returns on RMD

18.7%


10-Year Cumulative Returns

21.7%


7-Year Cumulative Returns

17.3%


5-Year Cumulative Returns

12.4%


3-Year Cumulative Returns

What are the long-term rolling returns for RMD?

FIve years rolling returns for ResMed.

Annualized Returns

Which funds bought or sold RMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
BAILLIE GIFFORD & CO
reduced
-10.78
-2,465,170
14,034,800
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-48.75
-15,450,000
14,760,000
0.02%
2023-03-10
MATHER GROUP, LLC.
reduced
-18.74
-76,340
262,660
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-91.91
-29,338,000
2,450,000
0.01%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
reduced
-6.14
-183,527
1,563,470
0.10%
2023-02-28
Voya Investment Management LLC
reduced
-8.02
-9,772,390
69,622,600
0.10%
2023-02-28
CYPRESS ASSET MANAGEMENT INC/TX
unchanged
-
-13,228
275,772
0.10%
2023-02-28
Orin Green Financial, LLC
new
-
557,997
557,997
0.33%
2023-02-27
ST GERMAIN D J CO INC
added
11.42
-3,939,640
4,362
-%
2023-02-24
National Pension Service
added
2.63
-1,144,260
50,282,800
0.10%

1–10 of 46

Latest Funds Activity

Are funds buying RMD calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own RMD
No. of Funds

ResMed News

The Motley Fool Australia

Buy these ASX growth shares this week: experts.

The Motley Fool Australia,
3 hours ago

InvestorsObserver

Is Resmed Inc (RMD) Stock a Smart Value?.

InvestorsObserver,
4 days ago

DirectorsTalk Interviews

Schedule 13G FIlings of ResMed

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
wcm investment management, llc
2.6%
3,832,642
SC 13G/A
Feb 09, 2023
vanguard group inc
11.63%
17,028,881
SC 13G/A
Feb 07, 2023
blackrock inc.
9.4%
13,774,787
SC 13G/A
Feb 10, 2022
wcm investment management, llc
6.21%
9,046,150
SC 13G/A
Feb 10, 2022
vanguard group inc
11.06%
16,119,963
SC 13G/A
Feb 01, 2022
blackrock inc.
9.3%
13,561,224
SC 13G/A
Feb 10, 2021
vanguard group inc
10.65%
15,439,844
SC 13G/A
Feb 10, 2021
wcm investment management, llc
6.09%
8,821,570
SC 13G/A
Feb 01, 2021
blackrock inc.
9.7%
14,073,568
SC 13G/A
Feb 12, 2020
vanguard group inc
10.98%
15,790,293
SC 13G/A

RMD Fair Value

ResMed fair value in different scenarios

The table shows the Fair Value estimates for ResMed for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

84.10

-60.20%

105.11

-50.25%

137.13

-35.10%

173.47

-17.90%

201.39

-4.68%
Current Inflation

77.21

-63.46%

95.03

-55.02%

121.62

-42.44%

151.83

-28.14%

174.96

-17.19%
Very High Inflation

68.73

-67.47%

82.90

-60.76%

103.39

-51.06%

126.78

-39.99%

144.63

-31.55%

Historical ResMed Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of ResMed

View All Filings
Date Filed Form Type Document
Mar 16, 2023
4
Insider Trading
Mar 15, 2023
144
Notice of Insider Sale Intent
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 03, 2023
144
Notice of Insider Sale Intent
Feb 22, 2023
4
Insider Trading
Feb 16, 2023
4
Insider Trading
Feb 16, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading
Feb 10, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for RMD

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-03
Ghoshal Kaushik
sold
-220,000
220
-1,000
president, saas business
2023-03-03
PENDARVIS DAVID
sold
-325,035
216
-1,500
chief administrative officer
2023-02-17
Sandercock Brett
sold
-2,152,200
215
-10,000
chief financial officer
2023-02-15
Douglas Robert Andrew
sold
-320,250
213
-1,500
president and coo
2023-02-15
Farrell Michael J.
acquired
327,788
57.76
5,675
chief executive officer
2023-02-15
Farrell Michael J.
sold
-1,219,140
214
-5,675
chief executive officer
2023-02-13
Sandercock Brett
sold
-860,000
215
-4,000
chief financial officer
2023-02-03
PENDARVIS DAVID
sold
-336,750
224
-1,500
chief administrative officer
2023-02-02
Drexler Karen
sold
-134,589
226
-594
-
2023-01-17
Farrell Michael J.
sold
-1,273,270
224
-5,675
chief executive officer

1–10 of 50

About ResMed

RMD Income Statement

2022-12-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands
3 Months Ended6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Net revenue$ 1,033,744,000$ 894,874,000$ 1,984,038,000$ 1,798,890,000
Cost of sales (exclusive of amortization shown separately below)446,724,000379,325,000849,834,000765,993,000
Amortization of acquired intangible assets7,305,00011,231,00013,680,00022,289,000
Total cost of sales454,029,000390,556,000863,514,000788,282,000
Gross profit579,715,000504,318,0001,120,524,0001,010,608,000
Operating Expenses    
Selling, general, and administrative211,672,000185,362,000404,860,000362,082,000
Research and development69,874,00062,507,000133,062,000122,457,000
Amortization of acquired intangible assets9,563,0007,738,00017,513,00015,445,000
Acquisition related expenses8,412,00009,157,0000
Total operating expenses299,521,000255,607,000564,592,000499,984,000
Income from operations280,194,000248,711,000555,932,000510,624,000
Other income (loss), net:    
Interest (expense) income, net(10,338,000)(5,948,000)(17,472,000)(11,308,000)
Loss attributable to equity method investments (note 5)(2,826,000)(1,914,000)(4,853,000)(3,300,000)
Gain (loss) on equity investments (note 5)8,368,000(4,404,000)5,088,0001,208,000
Other, net(1,707,000)841,000(3,211,000)(1,150,000)
Total other income (loss), net(6,503,000)(11,425,000)(20,448,000)(14,550,000)
Income before income taxes273,691,000237,286,000535,484,000496,074,000
Income taxes48,777,00035,535,000100,092,00090,710,000
Net income$ 224,914,000$ 201,751,000$ 435,392,000$ 405,364,000
Basic earnings per share (dollars per share)$ 1.53$ 1.38$ 2.97$ 2.78
Diluted earnings per share (dollars per share)1.531.372.952.76
Dividend declared per share (dollars per share)$ 0.44$ 0.42$ 1.68$ 0.84
Basic shares outstanding (000's) (shares)146,704145,990146,568145,835
Diluted shares outstanding (000's) (shares)147,405147,040147,367147,044
Total Sleep and Respiratory Care    
Net revenue$ 916,981,000$ 795,840,000$ 1,761,424,000$ 1,602,339,000
Cost of sales (exclusive of amortization shown separately below)406,303,000343,194,000770,146,000692,876,000
Amortization of acquired intangible assets1,343,0001,072,0002,572,0001,972,000
Software as a Service    
Net revenue116,763,00099,034,000222,614,000196,551,000
Cost of sales (exclusive of amortization shown separately below)40,421,00036,131,00079,688,00073,117,000
Amortization of acquired intangible assets$ 5,962,000$ 10,159,000$ 11,108,000$ 20,317,000

RMD Balance Sheet

2022-12-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Dec. 31, 2022
Jun. 30, 2022
Current assets:  
Cash and cash equivalents$ 253,199$ 273,710
Accounts receivable, net of allowances of $27,118 and $23,259 at December 31, 2022 and June 30, 2022, respectively672,271575,950
Inventories (note 3)988,955743,910
Prepaid expenses and other current assets (note 3)410,731337,908
Total current assets2,325,1561,931,478
Non-current assets:  
Property, plant and equipment, net (note 3)522,745498,181
Operating lease right-of-use assets128,222132,314
Goodwill (note 4)2,767,1791,936,442
Other intangible assets, net (note 3)586,857345,944
Deferred income taxes85,78379,746
Prepaid taxes and other non-current assets260,162171,748
Total non-current assets4,350,9483,164,375
Total assets6,676,1045,095,853
Current liabilities:  
Accounts payable196,003159,245
Accrued expenses312,169344,722
Operating lease liabilities, current22,42921,856
Deferred revenue133,909108,667
Income taxes payable (note 6)58,30444,893
Short-term debt, net (note 8)9,9009,916
Total current liabilities732,714689,299
Non-current liabilities:  
Deferred revenue102,80395,455
Deferred income taxes107,5409,714
Operating lease liabilities, non-current116,445120,453
Other long-term liabilities50,6035,974
Long-term debt, net (note 8)1,790,689765,325
Long-term income taxes payable (note 6)37,18348,882
Total non-current liabilities2,205,2631,045,803
Total liabilities2,937,9771,735,102
Commitments and contingencies (note 10)
Stockholders’ equity:  
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued00
Common stock, $0.004 par value, 350,000,000 shares authorized; 188,737,368 issued and 146,901,134 outstanding at December 31, 2022 and 188,246,955 issued and 146,410,721 outstanding at June 30, 2022588586
Additional paid-in capital1,710,7661,682,432
Retained earnings3,920,1973,613,736
Treasury stock, at cost, 41,836,234 shares at December 31, 2022 and June 30, 2022(1,623,256)(1,623,256)
Accumulated other comprehensive loss(270,168)(312,747)
Total stockholders’ equity3,738,1273,360,751
Total liabilities and stockholders’ equity$ 6,676,104$ 5,095,853